Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Let's Get Real – ANDA Approval Likely Takes More Than Two Years, US FDA Says

Executive Summary

Office of Generic Drugs Director Kathleen Uhl calls a two-cycle approval timeline a realistic expectation for ANDA approval, but would not say that most ANDAs will fall into the paradigm.


Related Content

US FDA May Start Missing ANDA User Fee Goals – In Order To Speed Approvals
Will GDUFA III Curtail Priority Assessments?
ANDA Sponsors Need To 'Slow Down' And Focus On Quality, US FDA Generics Director Says
FDA May Not Implement User Fee Workload Adjuster In PDUFA VI
ANDA Median Approval Times Still Rising, But What Does It Mean?
GDUFA II Reviews Start Strong With High First-Cycle Approval Rate
ANDA Reviews: First-Cycle Desired, But Two-Cycles OK?
ANDA Refuse-to-Receive Challenges Become More Common – And More Successful
First-Cycle Approval Rate Already High; Can PDUFA V Actually Boost It?
GDUFA Performance Goals For Fiscal Years 2013-2017





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts